Therapy-induced senescent tumor cells in cancer relapse

• Published in: Journal of the National Cancer Center Vol. 3; no. 4; pp. 273 - 278
• Main Authors: Song, Ke-Xin, Wang, Jun-Xian, Huang, De
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.12.2023; Elsevier
• Subjects: Cancer therapy; Relapse; Review; Tumor cell senescence; Relapse; Cancer therapy; Tumor cell senescence
• ISSN: 2667-0054; 2096-8663; 2667-0054
• DOI: 10.1016/j.jncc.2023.09.001

Cellular senescence is characterized by a generally irreversible cell cycle arrest and the secretion of bioactive factors known as the senescence-associated secretory phenotype (SASP). In an oncogenic context, senescence is considered a tumor suppressive mechanism as it prevents cell proliferation and inhibits the progression from pre-malignant to malignant disease. However, recent studies have demonstrated that senescent tumor cells, which could spontaneously exist within cancer tissues or arise in response to various cancer interventions (the so-called therapy-induced senescence, TIS), can acquire pro-tumorigenic properties and are capable of driving local and metastatic relapse. This highlights the complex and multifaceted nature of cellular senescence in cancer biology. Here, we summarize the current knowledge of the pathological function of therapy-induced senescent tumor cells and discuss possible mechanisms by which tumor cell senescence contributes to cancer relapse. We also discuss implications for future studies toward targeting these less appreciated cells.